Literature DB >> 15047217

Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines.

Sachin M Apte1, Corazon D Bucana, Jerald J Killion, David M Gershenson, Isaiah J Fidler.   

Abstract

OBJECTIVES: We determined the expression of platelet-derived growth factor (PDGF), PDGF-receptor (PDGF-R), and phosphorylated PDGF-R (p-PDGF-R) on tumor cells and tumor-associated endothelial cells in clinical specimens of human ovarian carcinoma and human ovarian cancer cells growing in culture and in the peritoneal cavity of nude mice.
METHODS: Ten specimens of high-grade serous ovarian carcinoma were analyzed using immunohistochemistry (IHC). IHC was used to detect ligand and receptor expression in the human ovarian cancer cells from Hey A8 and SKOV3ip1 growing in culture. Cells from these lines were also implanted orthotopically into the peritoneal cavity of nude mice. IHC was used to determine ligand and receptor expression in tumors that formed in the peritoneal cavity.
RESULTS: All 10 evaluable samples expressed both PDGF AA and BB on tumor cells. Tumor cells were positive for PDGF-Ralpha in 10/10 samples, PDGF-Rbeta in 8/10 samples, p-PDGF-Ralpha in 6/10 samples, and p-PDGF-Rbeta in 4/10 samples. p-PDGF-Ralpha was positive in 4/10 tumor-associated endothelial cell samples and p-PDGF-Rbeta was positive in 3/10 samples. Human ovarian cancer cells expressed PDGF, PDGF-R, and p-PDGF-R when growing in culture or in the peritoneal cavity of nude mice. PDGF-R and p-PDGF-R were also present on tumor-associated endothelial cells as demonstrated by simultaneous staining with CD31 antibody.
CONCLUSIONS: PDGF and the corresponding receptors were expressed in autochthonous human ovarian cancer lesions on both tumor cells and tumor-associated endothelial cells. The ligand and receptor were also present on Hey A8 and SKOV3ip1 human ovarian cancer cells growing in vitro and in the peritoneal cavity of nude mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047217     DOI: 10.1016/j.ygyno.2003.12.041

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  28 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.

Authors:  Pablo Vivas-Mejia; Juliana Maria Benito; Ariel Fernandez; Hee-Dong Han; Lingegowda Mangala; Cristian Rodriguez-Aguayo; Arturo Chavez-Reyes; Yvonne G Lin; Mark S Carey; Alpa M Nick; Rebecca L Stone; Hye Sun Kim; Francois-Xavier Claret; William Bornmann; Bryan T J Hennessy; Angela Sanguino; Zhengong Peng; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

3.  Hematogenous metastasis of ovarian cancer: rethinking mode of spread.

Authors:  Sunila Pradeep; Seung W Kim; Sherry Y Wu; Masato Nishimura; Pradeep Chaluvally-Raghavan; Takahito Miyake; Chad V Pecot; Sun-Jin Kim; Hyun Jin Choi; Farideh Z Bischoff; Julie Ann Mayer; Li Huang; Alpa M Nick; Carolyn S Hall; Cristian Rodriguez-Aguayo; Behrouz Zand; Heather J Dalton; Thiruvengadam Arumugam; Ho Jeong Lee; Hee Dong Han; Min Soon Cho; Rajesha Rupaimoole; Lingegowda S Mangala; Vasudha Sehgal; Sang Cheul Oh; Jinsong Liu; Ju-Seog Lee; Robert L Coleman; Prahlad Ram; Gabriel Lopez-Berestein; Isaiah J Fidler; Anil K Sood
Journal:  Cancer Cell       Date:  2014-07-14       Impact factor: 31.743

4.  Expression of c-Kit and PDGFRα in epithelial ovarian tumors and tumor stroma.

Authors:  Cunjian Yi; Li Li; Keming Chen; Shengrong Lin; Xiangqiong Liu
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

5.  An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

Authors:  Qing Sheng; Xinggang Liu; Eleanor Fleming; Karen Yuan; Huiying Piao; Jinyun Chen; Zeinab Moustafa; Roman K Thomas; Heidi Greulich; Anna Schinzel; Sara Zaghlul; David Batt; Seth Ettenberg; Matthew Meyerson; Birgit Schoeberl; Andrew L Kung; William C Hahn; Ronny Drapkin; David M Livingston; Joyce F Liu
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

6.  Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

Authors:  Hiroaki Itamochi
Journal:  World J Biol Chem       Date:  2010-07-26

7.  Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Authors:  Liz Y Han; Charles N Landen; Jose G Trevino; Jyotsnabaran Halder; Yvonne G Lin; Aparna A Kamat; Tae-Jin Kim; William M Merritt; Robert L Coleman; David M Gershenson; William C Shakespeare; Yihan Wang; Raji Sundaramoorth; Chester A Metcalf; David C Dalgarno; Tomi K Sawyer; Gary E Gallick; Anil K Sood
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

8.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Authors:  Chunhua Lu; Mian M K Shahzad; Myrthala Moreno-Smith; Yvonne G Lin; Nicholas B Jennings; Julie K Allen; Charles N Landen; Lingegowda S Mangala; Guillermo N Armaiz-Pena; Rosemarie Schmandt; Alpa M Nick; Rebecca L Stone; Robert B Jaffe; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2010-02-16       Impact factor: 4.742

9.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.

Authors:  Janna Paulsson; Tobias Sjöblom; Patrick Micke; Fredrik Pontén; Göran Landberg; Carl-Henrik Heldin; Jonas Bergh; Donal J Brennan; Karin Jirström; Arne Ostman
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

10.  A current review of targeted therapeutics for ovarian cancer.

Authors:  Susana M Campos; Sue Ghosh
Journal:  J Oncol       Date:  2010-01-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.